Chardan Capital Lowers Homology Medicines (NASDAQ:FIXX) Price Target to $8.00

Homology Medicines (NASDAQ:FIXXGet Rating) had its target price reduced by Chardan Capital from $10.00 to $8.00 in a research report sent to investors on Thursday, The Fly reports. They currently have a buy rating on the stock.

Several other brokerages have also recently issued reports on FIXX. Robert W. Baird lowered their price target on Homology Medicines from $10.00 to $9.00 and set an outperform rating on the stock in a research report on Wednesday, August 31st. BTIG Research lowered their price target on Homology Medicines from $29.00 to $12.00 and set a buy rating on the stock in a research report on Tuesday, August 16th. Royal Bank of Canada lowered their price target on Homology Medicines from $4.00 to $3.00 and set a sector perform rating on the stock in a research report on Friday, November 11th. Finally, Credit Suisse Group lowered their price target on Homology Medicines to $2.10 in a research report on Wednesday, November 16th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Homology Medicines currently has a consensus rating of Moderate Buy and an average price target of $8.57.

Homology Medicines Price Performance

Shares of Homology Medicines stock opened at $1.91 on Thursday. Homology Medicines has a 1-year low of $1.30 and a 1-year high of $5.34. The company has a market capitalization of $109.79 million, a P/E ratio of -19.10 and a beta of -0.19. The business’s fifty day moving average price is $1.58 and its two-hundred day moving average price is $1.93.

Institutional Trading of Homology Medicines

Several hedge funds and other institutional investors have recently modified their holdings of FIXX. Arizona State Retirement System acquired a new stake in shares of Homology Medicines in the first quarter worth $31,000. Virtu Financial LLC acquired a new stake in shares of Homology Medicines in the second quarter worth $34,000. Assenagon Asset Management S.A. acquired a new stake in Homology Medicines during the second quarter valued at $40,000. Bailard Inc. acquired a new stake in Homology Medicines during the second quarter valued at $47,000. Finally, Marshall Wace LLP boosted its position in Homology Medicines by 40.4% during the third quarter. Marshall Wace LLP now owns 30,175 shares of the company’s stock valued at $48,000 after purchasing an additional 8,689 shares during the last quarter. Institutional investors and hedge funds own 43.20% of the company’s stock.

About Homology Medicines

(Get Rating)

Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.

Featured Stories

The Fly logo

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.